0102 GMT - Sonic Healthcare gets a new bull at Bell Potter, where analyst Martyn Jacobs sees the pathology operator getting over what he calls its Covid-19 hangover. Jacobs initiates coverage of the stock with a buy rating, telling clients in a note that he expects Ebitda margins to start recovering from a rocky spell in FY 2025. Margins will expand by about 110 bps through fiscal FY he reckons. He says that growth is being driven by cost reductions, recent acquisitions, and a normalization of organic operations following Covid-driven disruption. Bell Potter puts a A$33.70 target price on the stock, which is up 1.0% at A$26.49. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 18, 2025 21:02 ET (01:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.